发明授权
US07968097B2 Identification of Hla-A2-presented T-cell epitopes derived from the oncofoetal antigen-immature laminin receptor protein and uses thereof
有权
鉴定来源于oncofoetal抗原 - 未成熟层粘连蛋白受体蛋白的Hla-A2呈递的T细胞表位及其用途
- 专利标题： Identification of Hla-A2-presented T-cell epitopes derived from the oncofoetal antigen-immature laminin receptor protein and uses thereof
- 专利标题（中）： 鉴定来源于oncofoetal抗原 - 未成熟层粘连蛋白受体蛋白的Hla-A2呈递的T细胞表位及其用途
-
申请号： US11912668申请日： 2006-04-26
-
公开(公告)号： US07968097B2公开(公告)日： 2011-06-28
- 发明人: Matthias Zeis
- 申请人： Matthias Zeis
- 申请人地址： DE Tuebingen
- 专利权人： Immatics Biotechnologies GmbH
- 当前专利权人： Immatics Biotechnologies GmbH
- 当前专利权人地址： DE Tuebingen
- 代理机构： Baker Donelson Bearman, Caldwell & Berkowitz, PC
- 优先权： EP05009095 20050426
- 国际申请： PCT/EP2006/003888 WO 20060426
- 国际公布： WO2006/114307 WO 20061102
- 主分类号： A61K38/00
- IPC分类号： A61K38/00 ; A61K38/04 ; A61K39/00 ; C07K7/00 ; C07K17/00
摘要：
The present invention relates to the immunotherapB of cancer, in particular several tumor entities including hematological malignancies. The present invention relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class I or II molecules of human oncofoetal antigen immature laminin receptor (OFA/iLR), which can be used in vaccine compositions for eliciting anti-tumor immune responses.
公开/授权文献
信息查询
IPC分类:
